Prima BioMed Price to Book Ratio 2006-2020 | IMMP

Historical price to book ratio values for Prima BioMed (IMMP) over the last 10 years. The current price to book ratio for Prima BioMed as of October 22, 2021 is 6.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Prima BioMed Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 4.31 inf
2017-03-31 2.44 0.00
2016-12-31 2.34 0.00
2016-06-30 3.23 0.00
2015-12-31 3.80 0.00
2015-06-30 4.83 0.00
2014-12-31 2.23 0.00
2014-06-30 3.87 0.00
2013-12-31 3.67 0.00
2013-06-30 6.98 0.00
2012-12-31 11.43 0.00
2012-06-30 15.30 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.368B $0.003B
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76